

Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"

Tressie Herrmann¹

¹ Unicancer

Potential competing interests: No potential competing interests to declare.

This article is well conducted and provides us with guidelines on the use of antiresorptive drugs for patients with metastatic cancers in bone.

The points discussed including duration of treatment, cost and major adverse effects are clear and contribute to a better use of these treatments.

I support the publication of this article and strongly recommend that these recommendations be extended to more centers managing these types of patients.